Search

everythinglearnresearchcommunity

for

Search:↓

Different types of fibroblasts play specific roles in wound healing and cancer, which could help improve treatments.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Vacuum massage may improve skin elasticity and induce changes in skin cells, but evidence for treating burn scars is insufficient and more research is needed.

Infliximab may cause hair loss in Crohn's disease patients.

Fzd2 is important for skin and hair development through various signaling ways.

JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.

New cytokine-targeted therapies show promise for treating alopecia areata.

Low-dose metformin may help hair regrowth and reduce inflammation in CCCA.

Cholesterol balance is important for hair health, and problems with it can lead to hair loss conditions.

Scarring alopecias are complex hair loss disorders that require early treatment to prevent permanent hair loss.

A new treatment using AGED to modulate PPAR-γ shows promise for treating scarring hair loss by protecting and repairing hair follicle cells.

Scarring alopecia affects different hair follicle stem cells than nonscarring alopecia, and the infundibular region could be a new treatment target.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Hair root sheaths are more common in non-scarring hair loss and help diagnose the type of hair loss.

The document concludes that primary scarring alopecias cause permanent hair loss, have unpredictable outcomes, and lack definitive treatments, requiring personalized care.

About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

Targeting the HEDGEHOG-GLI1 pathway could help treat keloids.

Early diagnosis and new treatments are crucial to prevent permanent hair loss in scarring alopecia.

Women with scarring alopecia are less likely to have used hormone replacement therapy or oral contraceptives compared to those with female pattern hair loss.

Activating the Wnt/β-catenin pathway could lead to new hair loss treatments.

Acne is caused by genetics, diet, hormones, and bacteria, with treatments not yet curative.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Low vitamin D might be linked to certain types of hair loss, and supplements could help, but more research is needed.

The conclusion is that better understanding and more research are needed to effectively manage follicular and scarring disorders in skin of color, with an emphasis on patient education and cultural awareness.

Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.

A substance called Vascular Endothelial Growth Factor can protect certain hair follicle stem cells from damage caused by androgens, suggesting a new possible treatment for hair loss.

The mTOR pathway proteins are altered in the hair follicles of patients with Lichen Planopilaris and Frontal Fibrosing Alopecia.

Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.

Non-scarring hair loss can be diagnosed with two 4mm punch biopsies, one cut vertically and the other transversely.